ADME toxicology testing market seen nearly doubling by 2035

The global ADME toxicology testing market is projected to grow from $7.79 billion in 2026 to $17.48 billion by 2035, driven by FDA rule changes, rising pharma R&D spending and faster adoption of in vitro and in silico testing. The report also points to rapid growth in Asia-Pacific and a shift toward organ-on-chip and AI-based screening tools. Why it matters: - ADME toxicology testing is becoming a bigger gatekeeper in drug development as regulators and drugmakers move away from animal testing and toward cell-based, computational and organ-on-chip methods. - The market’s projected rise to $17.48 billion by 2035 signals more spending on preclinical safety tools across pharma, biotech and contract research organizations. What happened: - The global ADME toxicology testing market was estimated at $7.12 billion in 2025 and is projected to reach $7.79 billion in 2026. - The market is forecast to nearly double to $17.48 billion by 2035, growing at a 9.38% CAGR from 2026 to 2035. - The report uses audited CRO revenues, FDA and EMA regulatory milestone data, and bottom-up modeling across technology, method, application and end-user segments. - The report was published June 9, 2026. - A sample request and customization options were offered through the market research firm’s sample page and customization page . The details: - FDA Modernization Act 2.0 eliminated the federal mandate for animal testing in drug approval and opened the door for in vitro toxicity assay data and in silico prediction outputs in IND applications. - By mid-2024, the FDA had accepted alternative method data in more than 35 new drug submissions, up from 2021 levels. - The policy shift is estimated to have redirected about $800 million a year in preclinical budgets toward cell-based and computational testing platforms. - Global pharmaceutical R&D spending surpassed $260 billion in 2024. - Oncology accounts for about 41% of active clinical trials worldwide, increasing demand for hepatotoxicity screening and pharmacokinetics safety profiling. - Cell culture technology holds the largest segment share at about 44%, supported by primary hepatocyte assays, Caco-2 permeability studies, and adoption of 3D spheroid and organ-on-chip workflows. - Molecular imaging technology is the second-fastest growing segment, projected to expand at a 10.6% CAGR through 2035. - Cellular assay accounts for about 36% of market revenue. - In-silico testing is forecast to grow at a 12.1% CAGR, the fastest rate in the report. - The report says machine learning models trained on multi-million-compound datasets are gaining regulatory acceptance and could replace early-stage wet-lab confirmation for up to 40% of candidate screening decisions by 2030. - North America leads with an estimated 38% share and $2.71 billion in market value in 2025. - Asia-Pacific is projected to grow at an 11.2% CAGR and reach $4.62 billion by 2035. - China’s NMPA regulatory overhaul has compressed IND filing timelines. - Chinese CROs conduct an estimated 28% of all global drug absorption testing studies outsourced by Western sponsors, double the 2019 share. - India’s Hyderabad–Bangalore corridor is emerging as a hub for in vitro toxicity assays, supported by the government’s INR 10,000 crore Biopharma SHAKTI initiative. - Europe holds about 27% of the market, supported by the EMA’s 2023 Regulatory Science Strategy and EUR 95 million in Horizon Europe funding for alternative testing methods. Between the lines: - The market’s growth is being shaped by two forces at once: regulatory pressure to modernize testing and financial pressure to speed up expensive drug pipelines. - The strongest momentum is shifting toward platforms that reduce time, cost and animal use while still producing data acceptable to regulators. - The rise of AI, organ-on-chip systems and molecular imaging suggests the ADME market is moving from a niche preclinical function toward a more central role in drug discovery strategy. - The report’s concentration data shows a market that is still led by large CROs but increasingly challenged by specialized software and microphysiological systems developers. - The top five players — Charles River Laboratories, Eurofins Scientific, Covance, WuXi AppTec and Evotec — control an estimated 30% to 36% of global revenue. - The Herfindahl-Hirschman Index of 800 to 1,200 points to moderate concentration and active competitive pressure. - Recent milestones include Beckman Coulter’s Cydem VT Automated Clone Screening System in early 2026, Insilico Medicine’s $80 million collaboration with Exelixis in September 2023, Insilico Medicine’s $500 million partnership with Menarini in January 2024, CN-Bio Innovations’ $21 million Series B round in April 2024, and FDA guidance in March 2026 formalizing microphysiological systems as supporting evidence in IND applications. What’s next: - More drug developers are likely to adopt in vitro, in silico and organ-on-chip tools as regulators expand acceptance of alternative testing evidence. - Asia-Pacific is poised to take a larger share of outsourced ADME work as China and India keep building regulatory and manufacturing capacity. - The report suggests computational screening could become embedded in early candidate selection before 2030, especially in oncology and cell and gene therapy programs. - Additional research links were listed for related markets, including drug discovery services, in vitro toxicology testing, bioanalytical testing services, pharmacovigilance, preclinical CRO, high-throughput screening, cell viability assays, pharmaceutical analytical testing outsourcing, biomarkers and drug screening. - More information is available through the firm’s research report page and social channels, including LinkedIn , Facebook , YouTube and X .